Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAAV2tYF-CB-hRS1 in X-linked Retinoschisis
NCT02416622Phase 2Completed
- Sponsor
- Beacon Therapeutics
- Start
- May 2015
- Primary completion
- Apr 2019
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of AGTC-001 in X-linked retinoschisis (XLRS), sponsored by Beacon Therapeutics. Started May 2015; status: completed.
02
Drugs
AGTC-001
03
Conditions
X-linked retinoschisis (XLRS)
Beyond the preview
Go deeper on NCT02416622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02416622.